- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04578444
Un protocolo de tratamiento de acceso ampliado de zanidatamab (ZW25) en pacientes con cáncer de vías biliares avanzado positivo para HER2
Uso de acceso ampliado de zanidatamab para el tratamiento de tumores sólidos avanzados positivos para HER2
This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Tipo de acceso ampliado
- Población de tamaño intermedio
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Barcelona, España, 08035
- Vall D'Hebron University Hospital
-
Madrid, España, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, España, 28040
- Fundacion Jimenez Diaz University Hospital - Autonomous University of Madrid
-
-
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85234
- NoCo Banner MD Anderson Cancer Center
-
-
California
-
Cerritos, California, Estados Unidos, 90603
- TOI Clinical Research
-
Salinas, California, Estados Unidos, 93901
- Salinas Valley Memorial Healthcare System
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
-
-
-
Besançon, Francia, 25030
- Jean Minjoz Hospital
-
Marseille, Francia, 13385
- Hopital Timone Marseille
-
Pessac, Francia, 33604
- Hopital Haut-Leveque - CHU Bordeaux
-
Villejuif, Francia, 94805
- Gustave Roussy Cancer Center
-
-
-
-
-
Candiolo, Italia, 10060
- ICCRS Candiolo
-
Milan, Italia, 20133
- Istituto Nazionale Tumori
-
Milan, Italia, 20072
- Istituto Clinico Humanitas
-
-
-
-
-
Harlow, Reino Unido, CM20 1QX
- The Princess Alexandra Hospital NHS Trust (Joanne Kwa, Pharmacist)
-
London, Reino Unido, WC1E 6AG
- UCLH Cancer Institute (Meera Desai, Pharmacist)
-
London, Reino Unido, WC1E 6JA
- HCA Healthcare UK
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically confirmed HER2-positive locally advanced or metastatic biliary tract cancer that has progressed after receipt of available therapies known to confer clinical benefit.
- Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50%
- Adequate organ function
- Ineligible to participate or has no access to an ongoing zanidatamab or other Zymeworks clinical study (e.g., ZW49 clinical study).
- Females of childbearing potential and non-sterile males must agree to practice highly effective methods of birth control for the duration of the study and for 12 months after the last dose of study drug. In addition, non-sterile males must avoid sperm donation for the duration of the study and for 12 months after the last dose of study drug.
Exclusion Criteria:
-
Participating in other studies involving investigational drug(s) ≤ 3 weeks before the first dose of zanidatamab.
-
Systemic anti-cancer therapy ≤ 3 weeks before the first dose of zanidatamab.
-
Radiotherapy ≤ 2 weeks of the first dose of zanidatamab
-
The following central nervous system (CNS) brain lesions are excluded from the study:
-
Untreated or unstable brain lesions requiring immediate local therapy or symptomatic CNS metastases.
-
Radiation treatment for CNS metastases within 4 weeks before the first dose of zanidatamab.
-
Known history of or ongoing leptomeningeal disease (LMD). If LMD has been reported radiographically, but is not suspected clinically by the investigator, the patient must be free of neurological symptoms of LMD.
-
The following CNS brain lesions are permitted:
- Stable brain lesions are permitted if stable, as defined by patients who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening.
-
-
Concurrent uncontrolled or active hepatobiliary disorders or untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, unresolved biliary obstruction, biloma or abscess. Any complications should be resolved within 2 weeks prior to the first dose of zanidatamab.
-
Active hepatitis
-
Infection with human immunodeficiency virus (HIV) with uncontrolled disease.
-
Females who are breastfeeding or pregnant, and females and males planning a pregnancy.
-
History of myocardial infarction or unstable angina within 6 months prior to enrollment, congestive heart failure (NYHA Class 3 or 4), or clinically significant cardiac disease
-
QTc Fridericia (QTcF) > 470 ms assessed within 30 days of screening
-
Acute or chronic uncontrolled pancreatitis or Child-Pugh Class C liver disease
Plan de estudios
¿Cómo está diseñado el estudio?
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ZWI-ZW25-EAP
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .